Clinical Trial Update: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease [Phase 2]

View source ↗

Summary

A Phase 2 exploratory study is evaluating an anti-BCMA-CD19 CAR-T cell therapy for relapsed or refractory IgG4-related disease; the trial is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Anti-BCMA-CD19 CAR-T cell therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: IgG4 Related Disease, B-cell Mediated Autoimmune Disorders | Phase 2 | Status: RECRUITING